If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
291
results.
Updated on
15/07/2026 [08:14:00]
Results 25 to 50 of 291
Absstract of: US20260184772A1
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
Absstract of: WO2026142185A1
In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.
Absstract of: WO2018218193A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
Absstract of: US12668835B1
A sample holder includes a first member featuring a first retaining mechanism configured to retain a first substrate that includes a sample, a second member featuring a second retaining mechanism configured to retain a second substrate that includes a reagent medium, and an alignment mechanism connected to at least one of the first and second members, and configured to align the first and second members such that the sample contacts at least a portion of the reagent medium when the first and second members are aligned.
Absstract of: KR20260101594A
본원은 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다. 더욱 상세하게, 본원은 아밀로이드 베타와의 결합력 및 선택성 증가로 정확도가 개선된 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다.
Absstract of: CN121263693A
Provided herein are methods for detecting proteins and/or protein variants thereof, the methods comprising adding to a biological sample one or more small molecules and one or more protein binding agents wherein a protein crown is formed on a surface of the protein binding agent, and detecting the protein and/or protein variants thereof in the protein crown by antibody-based technology or proteomic technology. Also provided herein are methods for detecting one or more biomarkers or patterns of one or more biomarkers associated with a disease or health profile condition, as well as methods of diagnosing or predicting a disease in a subject. Compositions comprising one or more small molecules, one or more protein binding agents, and one or more biological samples are also provided.
Absstract of: AU2020258381A1
Disclosed herein are methods for detecting a biological or chemical entity in a sample, wherein the biological or chemical entity is associated with extracellular vesicles. The methods disclosed comprise the steps of a) processing the sample, (b) using a detection assay to detect the presence of extracellular vesicles and to isolate the extracellular vesicles, (c) processing the extracellular vesicles to expose or release the biological or chemical entity, and (e) detecting the biological or chemical entity released from the extracellular vesicle. In certain embodiments, the extracellular vesicles are associated with proteins, glycoproteins, peptides, lipids, nucleic acids or other cellular components. The detection methods are useful for identifying the presence of microbial antigens related to
Absstract of: CN122277725A
本申请实施例提供了一种抗NFL蛋白的单克隆抗体组合及其用途。所述单克隆抗体组合包括第一抗体和第二抗体，第一抗体包括第一重链可变区和第一轻链可变区，第二抗体包括第二重链可变区和第二轻链可变区；第一重链可变区包括如SEQ ID NO:3‑5所示的三个互补决定区，第一轻链可变区包括如SEQ ID NO:6‑8所示的三个互补决定区；第二重链可变区包括如SEQ ID NO:11‑13所示的三个互补决定区；第二轻链可变区包括如SEQ ID NO:14‑16所示的三个互补决定区。本实施例提供的单克隆抗体组合具有优异的特异性和高亲和力，可用于体外定量检测血清中NFL浓度，为神经系统相关疾病的辅助诊断提供技术支持。
Absstract of: CN122283146A
0001 本发明提供了人源卵泡抑素样蛋白（FSTL1）作为特发性正常压力脑积水标记物的应用及检测方法及试剂盒，其中，人源卵泡抑素样蛋白（FSTL1）的NCBI Gene ID 11167，RefSeq mRNA编号为NM_007085.5，RefSeq蛋白编码为NP_009016.1，UniProt编号为Q12841。本发明解决了现有检测技术中存在的无法早期分子识别、标志物特异性不足、低丰度蛋白检测灵敏度不足的技术问题。
Absstract of: CN122283116A
本发明公开了一种神经轻链蛋白的检测试剂盒、方法及磁性水凝胶制备方法，本发明的检测试剂盒，包含磁性水凝胶偶联探针，神经轻链蛋白检测抗体，预激发液和激发液；其中，磁性水凝胶偶联探针为表面络合有顺磁性的纳米四氧化三铁粒子的含羧基聚合物球形颗粒。
Absstract of: CN122277723A
0001 本发明公开了检测载脂蛋白E4的抗体及其应用，具体涉及检测阿尔茨海默症血液标志物ApoE4的检测抗体和试剂盒，基于该抗体及试剂盒能够准确的检测载脂蛋白E4的存在。
Absstract of: CN122282992A
本发明提供了一种测定人血浆中β‑淀粉样蛋白42/40比率的质谱方法，包括采用¹5N稳定同位素标记的完整Aβ42和Aβ40蛋白作为内标，通过免疫沉淀技术对血浆样本进行提取与纯化，并利用Lys‑N蛋白酶解产生特征性肽段，最终通过液相色谱‑串联质谱进行靶向定量分析。Aβ42的特征肽段是Aβ28‑42 KGAIIGLMVGGVVIA；Aβ40的特征肽段是Aβ28‑40 KGAIIGLMVGGVV。相较于完整蛋白，本发明中的特征肽段不易发生聚集且在质谱中具有更高的电离效率，展现出优异的特异性、重复性与灵敏度，能够为阿尔茨海默症的诊断提供可靠依据。
Absstract of: CN122283145A
本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau181蛋白测定试剂盒及应用，本申请所述的抗试剂A和抗试剂B中的p‑Tau181抗体中的生物素和碱性磷酸酶发生反应，形成抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的反应结合到磁性微粒上，加入化学发光底物AMPPD，碱性磷酸酶催化AMPPD产生化学发光信号，通过光学检测系统测量发光强度，仪器自动通过工作曲线计算得出检测结果，本申请通过对试剂盒的抗试剂A和抗试剂B以及磁微粒试剂进行设计，能够精准捕获抗体并放大信号，有效的降低检测限，提升试剂盒的综合性能。
Absstract of: CN122291031A
0001 本发明公开了一种基于不良结局路径模型的污染物联合暴露毒性风险预警方法，建立联合暴露体系，将受试对象分为空白对照组、单一污染物暴露组及联合暴露组，在预设环境条件下进行暴露；在暴露过程中设置两个采样时间点，包括第一采样时间点和第二采样时间点；获取受试对象多层级检测指标数据，包括生化指标、组织病理指标、表面超微结构指标和/或基因表达指标；基于所述多层级检测指标数据，识别不良结局路径中的分子起始事件、早期关键事件、后期关键事件及不良结局，建立分子起始事件至关键事件再至不良结局的因果关联链条；根据不良结局的出现情况，输出分级风险预警结果。联合暴露体系中的受试对象为鱼类，污染物为全氟辛酸和聚苯乙烯微塑料。
Absstract of: EP4560314A1
0001 The present invention relates to an ex vivo method for mapping the spatiotemporal electrophysiological dynamics and spatial transcriptional profiles of cells in a functional neuronal cell assembly, comprising simultaneous recording and analysis of spatial data of molecular and electrical network activity down to the level of individual cells using high-density electrical biosensors, spatial transcriptomics, optical imaging, and advanced computational strategies. The invention further relates to methods for identifying the composition of a functional neuronal assembly, for monitoring the spatiotemporal electrophysiological dynamics and transcriptional profiles of cells in a functional neuronal cell assembly, for monitoring the cellular composition of a functional neuronal assembly, or for identifying a compound having an effect on the spatial electrophysiological and transcriptional dynamics and/or for identifying the composition of cells in a functional neuronal cell assembly based on the dynamics as detected, as well as devices and uses thereof. The invention allows for a better understanding of disease mechanisms, and to find therapeutic targets and to develop new drugs and treatments.
Absstract of: CN122283142A
本发明公开了一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，属于体外诊断医疗器械技术领域，包括泪液采样器、微流控芯片和便携式读数器，泪液采样器用于将采集并预处理的泪液样本输送至微流控芯片，微流控芯片上设置有样品输入口，泪液采样器与样品输入口连接，微流控芯片上设置有用于检测生物标志物的微通道结构，且微流控芯片能置于便携式读数器的卡槽内，便携式读数器用于进行信号检测并对监测数据进行分析后输出诊断结果。本发明采用上述的一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，旨在实现阿尔茨海默病的早期、快速、高灵敏度诊断。
Absstract of: WO2022118944A1
The present invention addresses the problem of providing: a method for evaluating dementia; and a composition for preventing or treating deterioration in brain function, or maintaining or improving brain function. The intestinal microflora of healthy people, people with mild cognitive impairment, or patients suffering from Alzheimer's disease were compared. As a result, a microorganism belonging to the genus Faecalibacterium was selected as an intestinal microorganism associated with cognitive function. Furthermore, it has been found that Faecalibacterium prausnitzii having a specific DNA exhibits an effect of ameliorating brain function deterioration such as learning and memory impairment.
Absstract of: US20260176332A1
0000 The present application relates to a marker and a method for detecting inflammation-related diseases. The marker of the present application can stably exist in an ex vivo body fluid sample and does not gather on a cell membrane, so the detection result is very accurate. The marker can be widely applied to the medical detection of inflammation-related diseases, having good clinical application prospects.
Absstract of: US20260177562A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.
Absstract of: US20260176652A1
0000 In certain embodiments the present invention provides a method of treating hearing loss comprising: (a) administering a gene suppression agent that suppresses both copies of an endogenous gene causing the hearing loss; and (b) administering an exogenous wild-type allele engineered to resist suppression by the gene suppression agent. 0000 The present invention provides in certain embodiments a method of treating a genetic hearing loss (GHL) in a patient in need thereof comprising: (a) identifying a mutation in a GHL-causing gene, wherein the mutation causes GHL in the patient; and (b) administering to the patient a pharmaceutical composition comprising a therapeutic miRNA and a pharmaceutically acceptable carrier, wherein the GHL therapeutic miRNA is of 18 to 25 nucleotides in length and knocks-down the GHL-causing gene function at a higher level than it knocks-down gene function in a corresponding wild-type gene.
Absstract of: AU2024406255A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Absstract of: WO2026135697A1
Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Absstract of: US20260177563A1
0000 Disclosed is a sample analyzer comprising: a measurement unit configured to measure an analyte related to a dementia biomarker contained in a sample collected from a subject, the measurement unit comprising: a sample dispenser configured to aspirate the sample from a sample container and discharge the aspirated sample into a cuvette, a first reagent dispenser configured to aspirate a first reagent from a first reagent container and discharge the aspirated first reagent into the cuvette, wherein the first reagent immunologically reacts with the analyte, a second reagent dispenser configured to aspirate a second reagent from a second reagent container and discharge the aspirated second reagent into the cuvette, wherein the second reagent generates light corresponding to an amount of the reacted analyte, a detector configured to detect the generated light from a mixture of the sample, the first reagent, and the second reagent in the cuvette; a controller comprising a processor and programmed to obtain a measurement value of the analyte based on the light detected by the detector; a storage configured to store a reference value that specifies an outlier that may be caused by a factor other than dementia; and an output unit, wherein the controller is programmed to execute a determination on whether the measurement value is specified as the outlier based on the measurement value and the reference value, generate an analysis result of the dementia biomarker based on the mea
Absstract of: WO2026132413A1
The present invention relates to an antibody or antigen-binding fragment thereof, which binds to TDP-43, i.e. TAR DNA-binding protein 43, and to therapeutic and diagnostic uses thereof.
Nº publicación: WO2026132444A1 25/06/2026
Applicant:
CT HOSPITALIER UNIVERSITAIRE MONTPELLIER [FR]
UNIV MONTPELLIER [FR]
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
UNIVERSITE DE MONTPELLIER
Absstract of: WO2026132444A1
The present invention relates to in vitro methods for diagnosing or prognosing diseases and disorders associated with altered orexin-A levels. It further relates to in vitro methods for monitoring the effect of a treatment or the evolution of a disease or disorder associated with altered orexin-A levels. It also relates to the use of orexin-A fragment as biomarker for the in vitro diagnosis of diseases and disorders associated with altered orexin-A levels.
BOPI
Electronic site
